- Conditions
- Hernia
- Interventions
- ECLIPSIUM® System, Resorbable tacks (AbsorbaTack/SorbaFix)
- Device
- Lead sponsor
- Tissium
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Gainesville, Florida • Chicago, Illinois + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 4,513
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stroke
- Interventions
- Coherex WaveCrest® Left Atrial Appendage Occlusion System, Watchman® LAA Closure Device
- Device
- Lead sponsor
- Coherex Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 18 more
- Conditions
- Obesity
- Interventions
- Canagliflozin, Phentermine, Matching Placebo to Canagliflozin, Matching Placebo to Phentermine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more
- Conditions
- Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
- Interventions
- Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tamoxifen Citrate, Topotecan, Trametinib Dimethyl Sulfoxide
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 488
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 310 more
- Conditions
- Osteoarthritis, Avascular Necrosis, Congenital Hip Dysplasia, Traumatic Arthritis
- Interventions
- C2a - Taper™ Acetabular System
- Device
- Lead sponsor
- Biomet Orthopedics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 2
- States / cities
- Cedar Rapids, Iowa • Lexington, Kentucky
- Conditions
- Critical Illness
- Interventions
- Not listed
- Lead sponsor
- University of Melbourne
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Epilepsy
- Interventions
- pregabalin
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Fayetteville, Arkansas • Fullerton, California + 29 more
- Conditions
- Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
- Interventions
- Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 769 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 67
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more
- Conditions
- Lennox-Gastaut Syndrome
- Interventions
- Rufinamide, Any other approved Antiepileptic Drug
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 1 Year to 3 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 22
- States / cities
- San Diego, California • Aurora, Colorado • Washington D.C., District of Columbia + 19 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed, Vibostolimab, Boserolimab, MK-4830, MK-0482, Ifinatamab Deruxtecan (I-DXd), HER3-DXd
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2032
- U.S. locations
- 18
- States / cities
- Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more
- Conditions
- Desmoplastic Melanoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Pembrolizumab, Positron Emission Tomography, Therapeutic Conventional Surgery
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 280
- States / cities
- Fairbanks, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 199 more
- Conditions
- Pleuropulmonary Blastoma
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Dexrazoxane, Doxorubicin, Echocardiography Test, Ifosfamide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Patient Observation, Positron Emission Tomography, Topotecan, Ultrasound Imaging, Vincristine
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 71 more
- Conditions
- Cocaine Dependence
- Interventions
- Cocaine, Placebo
- Drug
- Lead sponsor
- Joshua A. Lile, Ph.D.
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Lung Cancer
- Interventions
- monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody 3H1 anti-idiotype vaccine, radiation therapy
- Biological · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 218
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- Rilvegostomig, Pembrolizumab
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 39
- States / cities
- La Mesa, California • Los Alamitos, California • Newark, Delaware + 36 more
- Conditions
- Venous Thrombosis, Pulmonary Embolism
- Interventions
- Apixaban, Enoxaparin, Warfarin, Enoxaparin Placebo, Apixaban Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 69 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- BIIB017 (peginterferon beta-1a), Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Ponte Vedra Beach, Florida • Atlanta, Georgia + 9 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Molecular tumor board assisted care
- Other
- Lead sponsor
- Timothy Mullett
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 659 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Rosiglitazone, Metformin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 55 Years to 80 Years · Female only
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Huntington Park, California • Los Angeles, California + 15 more
- Conditions
- Crohn's Disease
- Interventions
- abatacept, placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD
- Interventions
- Aclidinium Bromide, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 130 Years
- Enrollment
- 3,635 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 433
- States / cities
- Birmingham, Alabama • Florence, Alabama • Foley, Alabama + 334 more
- Conditions
- Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Kidney Neoplasm, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Desmoid Fibromatosis, Ganglioneuroma, Lymphoproliferative Disorder, Malignant Neoplasm, Malignant Solid Neoplasm, Melanocytic Neoplasm, Myeloproliferative Neoplasm, Neoplasm of Uncertain Malignant Potential, Neuroendocrine Neoplasm, Stromal Neoplasm
- Interventions
- Cytology Specimen Collection Procedure, Medical Chart Review
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 25 Years
- Enrollment
- 75,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2030
- U.S. locations
- 246
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 177 more
- Conditions
- Cancer
- Interventions
- Freenome Test
- Diagnostic Test
- Lead sponsor
- Freenome Holdings Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 7,435 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Springdale, Arkansas + 62 more
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
- Drug · Device
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 25 more